These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6318789)

  • 1. Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
    Evans BD; Smith IE; Clutterbuck RD; Millar JL
    Br J Cancer; 1984 Jan; 49(1):43-7. PubMed ID: 6318789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.
    Evans BD; Smith IE; Millar JL
    Br J Cancer; 1983 Feb; 47(2):215-9. PubMed ID: 6297529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
    J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to relate the anti-tumour action of cyclophosphamide with the immunogenicity of two murine fibrosarcomas.
    Evans R
    Int J Cancer; 1978 May; 21(5):611-6. PubMed ID: 659026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose preoperative systemic cyclophosphamide for the prevention of bladder tumor implantation in F344 rats.
    See WA; Crist SA; Boileau MA; Williams RD
    Cancer Res; 1991 Mar; 51(5):1373-7. PubMed ID: 1997175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
    Law MP; Hirst DG; Brown JM
    Br J Cancer; 1981 Aug; 44(2):208-18. PubMed ID: 7272187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination.
    Andrade-Mena CE
    Int J Tissue React; 1994; 16(2):95-103. PubMed ID: 7960506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
    Twentyman PR
    Br J Cancer; 1981 Jun; 43(6):745-55. PubMed ID: 6264941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual damage in mouse lungs at long intervals after cyclophosphamide treatment.
    Travis EL; Bucci L; Fang MZ
    Cancer Res; 1990 Apr; 50(7):2139-45. PubMed ID: 2317805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
    Shorthouse AJ; Jones JM; Steel GG; Peckham MJ
    Br J Cancer; 1982 Jul; 46(1):35-44. PubMed ID: 6285948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bioassay for cyclophosphamide in blood, lung and tumour.
    Begg AC; Smith KA
    Br J Cancer; 1984 Jan; 49(1):49-55. PubMed ID: 6691899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fractional cyclophosphamide dosage on sheep red blood cell-delayed-type hypersensitivity response in mice.
    Rondinone SN; Giovanniello OA; Barrios HA; Nota NR
    J Immunol; 1983 Apr; 130(4):1600-3. PubMed ID: 6220061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow and peripheral blood modifications in C57BL mice administered with cyclophosphamide and levan.
    Siegal A; Kopel S; Bar-Sela S; Davidai G; Yavetz H; Leibovici J
    In Vivo; 1988; 2(5):349-59. PubMed ID: 2979857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of c-myb transcription in autoimmune disease by cyclophosphamide.
    Mountz JD; Mushinski JF; Smith HR; Klinman DM; Steinberg AD
    J Immunol; 1985 Oct; 135(4):2417-22. PubMed ID: 4031495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
    Anderson KC; Humphrey RL; Sensenbrenner LL
    Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.